Risk for squamous-cell carcinoma (SCC) of the buccal cavity and skin, according to chronic GVHD and duration of therapy
. | SCC buccal cavity . | . | . | . | SCC skin . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk factors . | Case patients, no. . | Control patients, no. . | RR* . | 95% CI . | Case patients, no. . | Control patients, no. . | RR . | 95% CI . | ||||||
| Model 1: chronic GVHD | ||||||||||||||
| No | 5 | 24 | 1.00 | Reference | 3 | 29 | 1.00 | Reference | ||||||
| Yes | 19 | 42 | 2.35 | 0.70-7.93 | 16 | 22 | 14.46 | 1.84-113.3 | ||||||
| Unknown | 0 | 1 | - | - | - | - | - | - | ||||||
| Model 2: total duration of prophylaxis, acute and chronic GVHD therapy | ||||||||||||||
| None, less than 12 mo | 7 | 34 | 1.00 | Reference | 7 | 32 | 1.00 | Reference | ||||||
| 12-23 mo | 4 | 18 | 1.14 | 0.28-4.67 | 3 | 12 | 2.00 | 0.38-10.36 | ||||||
| 24 mo or more | 13 | 14 | 5.65 | 1.53-20.79 | 9 | 7 | 12.00 | 2.02-71.38 | ||||||
| Unknown | 0 | 1 | - | - | - | - | - | - | ||||||
| Model 3: duration of chronic GVHD therapy | ||||||||||||||
| None, less than 12 mo | 9 | 40 | 1.00 | Reference | 8 | 41 | 1.00 | Reference | ||||||
| 12-23 mo | 4 | 17 | 0.99 | 0.25-3.93 | 3 | 6 | 2.32 | 0.42-12.91 | ||||||
| 24 mo or more | 11 | 9 | 6.76 | 1.71-26.69 | 8 | 4 | 20.30 | 2.41-171.0 | ||||||
| Unknown | 0 | 1 | - | - | - | - | - | - | ||||||
| Model 4: chronic GVHD drug therapy | ||||||||||||||
| None, other, no CSP, no AZA | 9 | 41 | 1.00 | Reference | 7 | 38 | 1.00 | Reference | ||||||
| CSP, no AZA | 3 | 13 | 0.78 | 0.17-3.51 | 2 | 8 | 1.23 | 0.13-11.78 | ||||||
| Any AZA | 11 | 11 | 5.47 | 1.41-21.16 | 10 | 5 | 20.84 | 2.57-169.1 | ||||||
| Unknown CSP/AZA | 1 | 2 | - | - | - | - | - | - | ||||||
. | SCC buccal cavity . | . | . | . | SCC skin . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk factors . | Case patients, no. . | Control patients, no. . | RR* . | 95% CI . | Case patients, no. . | Control patients, no. . | RR . | 95% CI . | ||||||
| Model 1: chronic GVHD | ||||||||||||||
| No | 5 | 24 | 1.00 | Reference | 3 | 29 | 1.00 | Reference | ||||||
| Yes | 19 | 42 | 2.35 | 0.70-7.93 | 16 | 22 | 14.46 | 1.84-113.3 | ||||||
| Unknown | 0 | 1 | - | - | - | - | - | - | ||||||
| Model 2: total duration of prophylaxis, acute and chronic GVHD therapy | ||||||||||||||
| None, less than 12 mo | 7 | 34 | 1.00 | Reference | 7 | 32 | 1.00 | Reference | ||||||
| 12-23 mo | 4 | 18 | 1.14 | 0.28-4.67 | 3 | 12 | 2.00 | 0.38-10.36 | ||||||
| 24 mo or more | 13 | 14 | 5.65 | 1.53-20.79 | 9 | 7 | 12.00 | 2.02-71.38 | ||||||
| Unknown | 0 | 1 | - | - | - | - | - | - | ||||||
| Model 3: duration of chronic GVHD therapy | ||||||||||||||
| None, less than 12 mo | 9 | 40 | 1.00 | Reference | 8 | 41 | 1.00 | Reference | ||||||
| 12-23 mo | 4 | 17 | 0.99 | 0.25-3.93 | 3 | 6 | 2.32 | 0.42-12.91 | ||||||
| 24 mo or more | 11 | 9 | 6.76 | 1.71-26.69 | 8 | 4 | 20.30 | 2.41-171.0 | ||||||
| Unknown | 0 | 1 | - | - | - | - | - | - | ||||||
| Model 4: chronic GVHD drug therapy | ||||||||||||||
| None, other, no CSP, no AZA | 9 | 41 | 1.00 | Reference | 7 | 38 | 1.00 | Reference | ||||||
| CSP, no AZA | 3 | 13 | 0.78 | 0.17-3.51 | 2 | 8 | 1.23 | 0.13-11.78 | ||||||
| Any AZA | 11 | 11 | 5.47 | 1.41-21.16 | 10 | 5 | 20.84 | 2.57-169.1 | ||||||
| Unknown CSP/AZA | 1 | 2 | - | - | - | - | - | - | ||||||
For SCC buccal cavity, there were 24 case patients and 67 control patients; for SCC skin, there were 19 case patients and 51 control patients.
Adjustment for smoking/alcohol consumption (at time of transplantation) in the buccal cavity model led to similar risk estimates